Oragenics, Inc. (OGEN) 8-K Summary
Business Context and Reporting Period
Oragenics, Inc. filed this Current Report on Form 8-K on August 26, 2026. The Company is incorporated in Florida and its common stock trades on the NYSE American under the symbol "OGEN". The filing addresses a regulatory notice received from the NYSE American regarding the Company's compliance with continued listing standards.
Key Financial Metrics
- Stockholders' Equity: $3.7 million as of June 30, 2026.
- Profitability: The Company reported net losses in each of its last five fiscal years ended December 31, 2025.
- Liquidity and Debt: The filing text does not provide specific values for cash flow, total debt, or current liquidity ratios.
Material Changes and Listing Status
The Company received notification from the NYSE American that it is no longer in compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide due to insufficient stockholders' equity relative to its history of net losses. Specifically, the Company failed to meet the $6 million equity threshold required for companies with net losses in their five most recent fiscal years.
As a result, the Company's common stock will continue to trade but will carry a ".BC" designation to indicate "below compliance" status. The Company is not currently eligible for any exemptions from these equity requirements.
Outlook, Management Commentary, and Risks
Compliance Plan: The Company must submit a plan of compliance to the NYSE American by September 25, 2026. This plan must detail how the Company intends to regain compliance by February 25, 2028, including specific milestones, quarterly financial projections, and strategic initiatives.
Management Strategy: Management intends to undertake transactions to achieve compliance, though there is no assurance this will be successful within the required timeframe.
Risks of Delisting: If the Company fails to submit an acceptable plan, fails to meet the February 25, 2028 deadline, or fails to make progress consistent with the plan, it will be subject to delisting. Potential negative impacts include:
- Reduced liquidity and market price of common stock.
- Reduced investor interest, impairing the ability to raise equity financing.
- Limited ability to use registration statements to offer freely tradable securities.
- Impaired ability to provide equity incentives to employees.
Key Facts for Investor Verification
- Verify the submission and acceptance of the compliance plan by the September 25, 2026 deadline.
- Monitor the ".BC" trading designation and any subsequent changes in stock liquidity or price.
- Review upcoming quarterly reports to assess progress toward the $6 million stockholders' equity target.
- Confirm whether the Company announces any strategic transactions or capital raises intended to restore compliance.